Skip to main content

Table 4 Estimated effects for models M1-M5 in the per-protocol (PP) analysis

From: Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations

 

M1

M2

M3

 

M4

 

M5

 
 

Est

SD

Est

SD

Est

SD

 

Est

SD

 

Est

SD

 

Study 3-1

2.47

1.01

−1.26

1.61

0.10

1.20

 

1.70

0.93

 

1.71

0.98

 

Study 4-1

1.03

1.26

1.33

1.40

0.78

1.04

 

1.07

1.04

 

1.03

1.12

 

Study 5-1

1.08

1.07

−1.88

1.23

−0.66

1.03

 

0.49

0.76

 

0.27

0.85

 

AQ

0.68

1.23

1.35

1.39

0.39

0.92

 

0.35

0.86

 

0.45

0.97

 

AMLM

2.04

1.30

1.50

1.20

1.35

1.07

 

1.65

1.15

 

1.71

1.23

 

ASCD

−1.76

1.37

−1.97

1.41

−1.25

1.24

 

−1.56

1.22

 

−1.69

1.26

 

ASSP

−1.77

1.10

2.31*

1.09

1.59

0.95

 

2.22*

1.07

 

2.00

1.20

 

DHPP

3.09*

0.74

2.93*

0.77

2.88*

0.68

 

2.27*

0.94

 

2.04*

1.04

 

γ D 21 (Day21-14)

−4.17*

0.60

−3.14*

1.50

−2.99*

0.72

 

−3.28*

0.57

 

−3.46

0.61

 

γ D 28 (Day28-14)

−3.87*

0.98

−3.04*

1.53

−3.03*

1.10

 

−3.69*

0.60

 

−3.91*

0.63

 

τ

6.57*

1.73

6.89*

1.75

7.52*

1.16

 

7.77*

1.00

 

7.40*

1.29

 

η

  

0.80*

0.26

      

0.34

0.29

 

DIC

636.69

371.24

302.32

 

536.82

 

532.07

 
  1. Study # 2, excluded. Est=estimation; SD=standard deviation; *: significant effect at the 5% level. τ: standard error of the subject random effect in modeling the logit- cumulated categorical variable. η: standard error of the subject random effect in modeling the log- variance (model 2).